Publications

Bhatia HS, Wandel S, Willeit P, Lesogor A, Bailey K, Ridker PM, Nestel P, Simes J, Tonkin A, Schwartz GG, Colhoun H, Wanner C, Tsimikas S. Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol-Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis Circulation. 2025 Jan 28;151(4):312-321. doi: 10.1161/CIRCULATIONAHA.124.069556. Epub 2024 Nov 4. (PMID: 39492722) (PMCID: PMC11771346) [Full Text]

Bhatia HS, Dweck MR, Craig N, Capoulade R, Pibarot P, Trainor PJ, Whelton SP, Rikhi R, Lidani KCF, Post WS, Tsai MY, Criqui MH, Shapiro MD, Budoff MJ, DeFilippis AP, Thanassoulis G, Tsimikas S. Oxidized Phospholipids and Calcific Aortic Valvular Disease J Am Coll Cardiol. 2024 Dec 17;84(25):2430-2441. doi: 10.1016/j.jacc.2024.08.070. Epub 2024 Nov 15. (PMID: 39545902) [Full Text]

Wilkinson MJ, Shapiro MD. Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay Arterioscler Thromb Vasc Biol. 2024 Dec;44(12):2396-2406. doi: 10.1161/ATVBAHA.124.319983. Epub 2024 Oct 31. (PMID: 39479765) (PMCID: PMC11602385) [Full Text]

Bhatia HS, Boccara F. Lipoprotein(a): Don't forget about secondary prevention Eur J Prev Cardiol. 2024 Nov 11;31(15):1888-1889. doi: 10.1093/eurjpc/zwae276. (PMID: 39166475) [Full Text]

Mohammadnia N, van Broekhoven A, Bax WA, Eikelboom JW, Mosterd A, Fiolet ATL, Tijssen JGP, Thompson PL, de Kleijn DPV, Tsimikas S, Cornel JH, Yeang C, El Messaoudi S. The Effects of Colchicine on Lipoprotein(a) and Oxidized Phospholipid Associated Cardiovascular Disease Risk Eur J Prev Cardiol. 2024 Oct 30:zwae355. doi: 10.1093/eurjpc/zwae355. Online ahead of print. (PMID: 39478683) [Full Text]

Ellberg CC, Bhatia HS. Strategies for management of patients with elevated lipoprotein(a) Curr Opin Lipidol. 2024 Oct 1;35(5):234-240. doi: 10.1097/MOL.0000000000000950. Epub 2024 Aug 14. (PMID: 39145610) (PMCID: PMC11387124) [Full Text]

Tsimikas S, Yeang C, Kronenberg F. In Search of an Accurate Measurement of LDL-C: Correction for Lp(a)-Cholesterol to Predict Clinical Outcomes J Am Coll Cardiol. 2024 Jul 9;84(2):178-181. doi: 10.1016/j.jacc.2024.05.009. (PMID: 38960511) [Full Text]

Patel J, Bhatia HS, Spitz JA. E pluribus unum-: Understanding Our Diversity and Disparities in Lp(a) Screening JACC Adv. 2024 May 1;3(6):100939. doi: 10.1016/j.jacadv.2024.100939. eCollection 2024 Jun. (PMID: 38938864) (PMCID: PMC11198614) [Full Text]

Razavi AC, Richardson LC, Coronado F, Dzaye O, Bhatia HS, Mehta A, Quyyumi AA, Vaccarino V, Budoff MJ, Nasir K, Tsimikas S, Whelton SP, Blaha MJ, Blumenthal RS, Sperling LS. Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a) Am J Prev Cardiol. 2024 Apr 27;18:100674. doi: 10.1016/j.ajpc.2024.100674. eCollection 2024 Jun. (PMID: 38741703) (PMCID: PMC11090055) [Full Text]

Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): Actionable strategies for risk assessment and mitigation Am J Prev Cardiol. 2024 Apr 3;18:100651. doi: 10.1016/j.ajpc.2024.100651. eCollection 2024 Jun. (PMID: 38646021) (PMCID: PMC11031736) [Full Text]

Patel N, Mittal N, Wilkinson MJ, Taub PR. Unique features of dyslipidemia in women across a lifetime and a tailored approach to management Am J Prev Cardiol. 2024 Apr 5;18:100666. doi: 10.1016/j.ajpc.2024.100666. eCollection 2024 Jun. (PMID: 38634109) (PMCID: PMC11021917) [Full Text]

Nurmohamed NS, van Rosendael AR, Danad I, Ngo-Metzger Q, Taub PR, Ray KK, Figtree G, Bonaca MP, Hsia J, Rodriguez F, Sandhu AT, Nieman K, Earls JP, Hoffmann U, Bax JJ, Min JK, Maron DJ, Bhatt DL. Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography Eur Heart J. 2024 May 27;45(20):1783-1800. doi: 10.1093/eurheartj/ehae190. (PMID: 38606889) (PMCID: PMC11129796) [Full Text]

Koschinsky ML, Bajaj A, Boffa MB, Dixon DL, Ferdinand KC, Gidding SS, Gill EA, Jacobson TA, Michos ED, Safarova MS, Soffer DE, Taub PR, Wilkinson MJ, Wilson DP, Ballantyne CM. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice J Clin Lipidol. 2024 May-Jun;18(3):e308-e319. doi: 10.1016/j.jacl.2024.03.001. Epub 2024 Apr 1. (PMID: 38565461) [Full Text]

Bhatia HS, Becker RC, Leibundgut G, Patel M, Lacaze P, Tonkin A, Narula J, Tsimikas S. Lipoprotein(a), platelet function and cardiovascular disease Nat Rev Cardiol. 2024 May;21(5):299-311. doi: 10.1038/s41569-023-00947-2. Epub 2023 Nov 8. (PMID: 37938756) (PMCID: PMC11216952) [Full Text]

Blaha MJ, Bhatia HS. Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy J Am Coll Cardiol. 2024 Apr 23;83(16):1540-1542. doi: 10.1016/j.jacc.2024.03.370. Epub 2024 Mar 25. (PMID: 38537912) (PMCID: PMC11216951) [Full Text]

Wilkinson MJ, Bajaj A, Brousseau ME, Taub PR. Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran J Am Heart Assoc. 2024 Mar 19;13(6):e032031. doi: 10.1161/JAHA.123.032031. Epub 2024 Mar 8. (PMID: 38456415) (PMCID: PMC11010004) [Full Text]

Bhatia HS, Trainor P, Carlisle S, Tsai MY, Criqui MH, DeFilippis A, Tsimikas S. Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multi-Ethnic Study of Atherosclerosis J Am Heart Assoc. 2024 Feb 6;13(3):e033562. doi: 10.1161/JAHA.123.033562. Epub 2024 Jan 31. (PMID: 38293935) (PMCID: PMC11056170) [Full Text]

Rogers MA, Bartoli-Leonard F, Zheng KH, Small AM, Chen HY, Clift CL, Asano T, Kuraoka S, Blaser MC, Perez KA, Natarajan P, Yeang C, Stroes ESG, Tsimikas S, Engert JC, Thanassoulis G, O'Donnell CJ, Aikawa M, Singh SA, Aikawa E. Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease Circulation. 2024 Jan 30;149(5):391-401. doi: 10.1161/CIRCULATIONAHA.123.066822. Epub 2023 Nov 8. (PMID: 37937463) (PMCID: PMC10842618) [Full Text]

Ma GS, Chiou TT, Wilkinson MJ. Is Lipoprotein(a) Clinically Actionable with Today's Evidence? The Answer is Yes Curr Cardiol Rep. 2023 Oct;25(10):1175-1187. doi: 10.1007/s11886-023-01937-z. Epub 2023 Aug 26. (PMID: 37632608) (PMCID: PMC10651710) [Full Text]

Bhatia HS. Aspirin and lipoprotein(a) in primary prevention Curr Opin Lipidol. 2023 Oct 1;34(5):214-220. doi: 10.1097/MOL.0000000000000891. Epub 2023 Jul 31. (PMID: 37527183) (PMCID: PMC11216950) [Full Text]

Bhatia HS, Rikhi R, Allen TS, Yeang C, Guan W, Garg PK, Tsai MY, Criqui MH, Shapiro MD, Tsimikas S. Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis Atherosclerosis. 2023 Sep;381:117217. doi: 10.1016/j.atherosclerosis.2023.117217. Epub 2023 Aug 9. (PMID: 37607461) (PMCID: PMC10659123) [Full Text]

de Boer LM, Wiegman A, Kroon J, Tsimikas S, Yeang C, Peletier MC, Revers A, Kastelein JJP, Zwinderman AH, Hutten BA. Lipoprotein(a) and carotid intima-media thickness in children with familial hypercholesterolaemia in the Netherlands: a 20-year follow-up study Lancet Diabetes Endocrinol. 2023 Sep;11(9):667-674. doi: 10.1016/S2213-8587(23)00156-0. Epub 2023 Jul 21. (PMID: 37487514) [Full Text]

Dastmalchi LN, German CA, Taub PR. High density lipoprotein: When to rethink too much of a good thing Am J Prev Cardiol. 2023 Jun 22;15:100511. doi: 10.1016/j.ajpc.2023.100511. eCollection 2023 Sep. (PMID: 37434863) (PMCID: PMC10331407) [Full Text]

Kuo SZ, Cepin S, Bergstrom J, Siddiqi H, Jung J, Lopez S, Huang DQ, Taub P, Amangurbanova M, Loomba R. Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes Aliment Pharmacol Ther. 2023 Sep;58(6):585-592. doi: 10.1111/apt.17637. Epub 2023 Jul 11. (PMID: 37431679) (PMCID: PMC10792531) [Full Text]

Tsimikas S, Bhatia HS, Erlinge D. Clinical trials to improve outcomes in patients with elevated Lp(a) undergoing PCI: The time has arrived J Clin Lipidol. 2023 Sep-Oct;17(5):567-570. doi: 10.1016/j.jacl.2023.06.005. Epub 2023 Jul 1. (PMID: 37419784) [Full Text]

Shapiro MD, Taub PR, Louie MJ, Lei L, Ballantyne CM. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials Atherosclerosis. 2023 Aug;378:117182. doi: 10.1016/j.atherosclerosis.2023.06.973. Epub 2023 Jun 29. (PMID: 37517922) [Full Text]

Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease Vasc Health Risk Manag. 2023 Jul 6;19:421-431. doi: 10.2147/VHRM.S338424. eCollection 2023. (PMID: 37434791) (PMCID: PMC10332363) [Full Text]

Jackson CL, Garg PK, Guan W, Tsai MY, Criqui MH, Tsimikas S, Bhatia HS. Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: The multi-ethnic study of atherosclerosis J Clin Lipidol. 2023 Jul-Aug;17(4):538-548. doi: 10.1016/j.jacl.2023.06.002. Epub 2023 Jun 17. (PMID: 37357049) (PMCID: PMC10691212) [Full Text]

Wilkinson MJ, Lepor NE, Michos ED. Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum J Am Heart Assoc. 2023 Jun 6;12(11):e028892. doi: 10.1161/JAHA.122.028892. Epub 2023 Jun 1. (PMID: 37260036) (PMCID: PMC10381990) [Full Text]

Wilkinson MJ, Xu I, Vasudevan RS, You H, Xu R, Taub PR. Trends in LDL-C following coronary angiography involving assessment by fractional flow reserve in obstructive vs non-obstructive coronary artery disease Am J Prev Cardiol. 2023 Feb 13;13:100473. doi: 10.1016/j.ajpc.2023.100473. eCollection 2023 Mar. (PMID: 36865903) (PMCID: PMC9971059) [Full Text]

Rikhi R, Bhatia HS, Schaich CL, Ashburn N, Tsai MY, Michos ED, Chevli PA, Herrington DM, Tsimikas S, Shapiro MD. Association of Lp(a) (Lipoprotein[a]) and Hypertension in Primary Prevention of Cardiovascular Disease: The MESA Hypertension. 2023 Feb;80(2):352-360. doi: 10.1161/HYPERTENSIONAHA.122.20189. Epub 2022 Dec 13. (PMID: 36511156) (PMCID: PMC9983733) [Full Text]

Chiou TT, Tomasi K, Taub PR, Wilkinson MJ. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic J Clin Lipidol. 2023 Jan-Feb;17(1):73-77. doi: 10.1016/j.jacl.2022.10.009. Epub 2022 Nov 1. (PMID: 36371372) [Full Text]

Sykes AV, Patel N, Lee D, Taub PR. Integrating Advanced Lipid Testing and Biomarkers in Assessment and Treatment Curr Cardiol Rep. 2022 Nov;24(11):1647-1655. doi: 10.1007/s11886-022-01775-5. Epub 2022 Aug 24. (PMID: 36001215) [Full Text]

Bhatia HS, Wilkinson MJ. Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies J Clin Med. 2022 Oct 13;11(20):6040. doi: 10.3390/jcm11206040. (PMID: 36294361) (PMCID: PMC9604626) [Full Text]

Lacaze P, Bakshi A, Riaz M, Polekhina G, Owen A, Bhatia HS, Natarajan P, Wolfe R, Beilin L, Nicholls SJ, Watts GF, McNeil JJ, Tonkin AM, Tsimikas S. Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes J Am Coll Cardiol. 2022 Oct 4;80(14):1287-1298. doi: 10.1016/j.jacc.2022.07.027. (PMID: 36175048) (PMCID: PMC10025998) [Full Text]

Patel N, Mittal N, Choubdar P, Taub PR. Lipoprotein(a)—When to Screen and How to Treat. Curr Cardiovasc Risk Rep. 2022 Jul 11. 16. 10.1007/s12170-022-00698-8. [Full Text]

Bhatia HS, Ma GS, Taleb A, Wilkinson M, Kahn AM, Cotter B, Yeang C, DeMaria AN, Patel MP, Mahmud E, Reeves RR, Tsimikas S. Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis Atherosclerosis. 2022 May;349:144-150. doi: 10.1016/j.atherosclerosis.2022.01.022. Epub 2022 Jan 31. (PMID: 35144769) (PMCID: PMC9674369) [Full Text]

Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, Tsimikas S. Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol J Am Coll Cardiol. 2022 Mar 22;79(11):1035-1046. doi: 10.1016/j.jacc.2021.12.032. (PMID: 35300814) (PMCID: PMC8972555) [Full Text]

Ormiston CK, Rosander A, Taub PR. Heart-Healthy Diets and the Cardiometabolic Jackpot Med Clin North Am. 2022 Mar;106(2):235-247. doi: 10.1016/j.mcna.2021.11.001. (PMID: 35227427) [Full Text]

Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Beckman JA, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Dagogo-Jack S, de Boer IH, DeFronzo RA, Eckel RH, Einhorn D, Fonseca VA, Green JB, Grunberger G, Guerin C, Inzucchi SE, Jellinger PS, Kosiborod MN, Kushner P, Lepor N, Mende CW, Michos ED, Plutzky J, Taub PR, Umpierrez GE, Vaduganathan M, Weir MR. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases J Diabetes Complications. 2022 Feb;36(2):108101. doi: 10.1016/j.jdiacomp.2021.108101. Epub 2021 Dec 7. (PMID: 34922811) (PMCID: PMC9803322) [Full Text]

Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e48-e60. doi: 10.1161/ATV.0000000000000147. Epub 2021 Oct 14. (PMID: 34647487) (PMCID: PMC9989949) [Full Text]

Xu I, Taub PR. Baseline testosterone level may modulate statin efficacy Coron Artery Dis. 2021 Dec 1;32(8):713-714. doi: 10.1097/MCA.0000000000001032. (PMID: 33826543) [Full Text]

Bhatia HS, Yeang C, Baruch A, Yang X, Stroes ESG, Tsimikas S. PCSK9 Inhibition and Oxidized Phospholipids J Am Coll Cardiol. 2021 Sep 21;78(12):1288-1289. doi: 10.1016/j.jacc.2021.07.031. (PMID: 34531030) (PMCID: PMC10198455) [Full Text]

Bays HE, Taub PR, Epstein E, Michos ED, Ferraro RA, Bailey AL, Kelli HM, Ferdinand KC, Echols MR, Weintraub H, Bostrom J, Johnson HM, Hoppe KK, Shapiro MD, German CA, Virani SS, Hussain A, Ballantyne CM, Agha AM, Toth PP. Ten things to know about ten cardiovascular disease risk factors Am J Prev Cardiol. 2021 Jan 23;5:100149. doi: 10.1016/j.ajpc.2021.100149. eCollection 2021 Mar. (PMID: 34327491) (PMCID: PMC8315386) [Full Text]

Atar D, Jukema JW, Molemans B, Taub PR, Goto S, Mach F, CerezoOlmos C, Underberg J, Keech A, Tokgözoğlu L, Bonaca MP. New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? Atherosclerosis. 2021 Feb;319:51-61. doi: 10.1016/j.atherosclerosis.2020.12.013. Epub 2021 Jan 18. (PMID: 33476944) [Full Text]

McCormick D, Bhatt DL, Bays HE, Taub PR, Caldwell KA, Guerin CK, Steinhoff J, Ahmad Z, Singh R, Moreo K, Carter J, Heggen CL, Sapir T. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model J Manag Care Spec Pharm. 2020 Dec;26(12):1517-1528. doi: 10.18553/jmcp.2020.26.12.1517. (PMID: 33251993) (PMCID: PMC10391214) [Full Text]

Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels Eur Heart J. 2020 Jun 21;41(24):2275-2284. doi: 10.1093/eurheartj/ehz310. (PMID: 31111151) [Full Text]

Schnitzler JG, Hoogeveen RM, Ali L, Prange KHM, Waissi F, van Weeghel M, Bachmann JC, Versloot M, Borrelli MJ, Yeang C, De Kleijn DPV, Houtkooper RH, Koschinsky ML, de Winther MPJ, Groen AK, Witztum JL, Tsimikas S, Stroes ESG, Kroon J. Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation Circ Res. 2020 May 8;126(10):1346-1359. doi: 10.1161/CIRCRESAHA.119.316206. Epub 2020 Mar 12. (PMID: 32160811) (PMCID: PMC7208285) [Full Text]

Capoulade R, Torzewski M, Mayr M, Chan KL, Mathieu P, Bossé Y, Dumesnil JG, Tam J, Teo KK, Burnap SA, Schmid J, Gobel N, Franke UFW, Sanchez A, Witztum JL, Yang X, Yeang C, Arsenault B, Després JP, Pibarot P, Tsimikas S. ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis Heart. 2020 May;106(10):738-745. doi: 10.1136/heartjnl-2019-315840. Epub 2020 Feb 13. (PMID: 32054669) [Full Text]

Ma GS, Wilkinson MJ, Reeves RR, Yeang C, DeMaria AN, Cotter B, Patel M, Mahmud E, Tsimikas S. Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement Angiology. 2019 Apr;70(4):332-336. doi: 10.1177/0003319719826461. Epub 2019 Jan 30. (PMID: 30700108) [Full Text]

Yeang C, Hasanally D, Que X, Hung MY, Stamenkovic A, Chan D, Chaudhary R, Margulets V, Edel AL, Hoshijima M, Gu Y, Bradford W, Dalton N, Miu P, Cheung DY, Jassal DS, Pierce GN, Peterson KL, Kirshenbaum LA, Witztum JL, Tsimikas S, Ravandi A. Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids Cardiovasc Res. 2019 Jan 1;115(1):179-189. doi: 10.1093/cvr/cvy136. (PMID: 29850765) (PMCID: PMC6302283) [Full Text]

Capoulade R, Yeang C, Chan KL, Pibarot P, Tsimikas S. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial JAMA Cardiol. 2018 Dec 1;3(12):1212-1217. doi: 10.1001/jamacardio.2018.3798. (PMID: 30476957) (PMCID: PMC6583098) [Full Text]

Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials Diabetes Obes Metab. 2018 Jul;20(7):1632-1641. doi: 10.1111/dom.13273. Epub 2018 Mar 25. (PMID: 29493859) (PMCID: PMC6033097) [Full Text]

Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, Diehl C, Määttä A, Gaddis DE, Bowden K, Pattison J, MacDonald JG, Ylä-Herttuala S, Mellon PL, Hedrick CC, Ley K, Miller YI, Glass CK, Peterson KL, Binder CJ, Tsimikas S, Witztum JL. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice Nature. 2018 Jun;558(7709):301-306. doi: 10.1038/s41586-018-0198-8. Epub 2018 Jun 6. (PMID: 29875409) (PMCID: PMC6033669) [Full Text]

Viney NJ, Yeang C, Yang X, Xia S, Witztum JL, Tsimikas S. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide J Clin Lipidol. 2018 May-Jun;12(3):702-710. doi: 10.1016/j.jacl.2018.02.014. Epub 2018 Mar 1. (PMID: 29574075) [Full Text]

Senders ML, Que X, Cho YS, Yeang C, Groenen H, Fay F, Calcagno C, Meerwaldt AE, Green S, Miu P, Lobatto ME, Reiner T, Fayad ZA, Witztum JL, Mulder WJM, Pérez-Medina C, Tsimikas S. PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis J Am Coll Cardiol. 2018 Jan 23;71(3):321-335. doi: 10.1016/j.jacc.2017.11.036. (PMID: 29348025) (PMCID: PMC5995462) [Full Text]

Wilkinson MJ, Ma GS, Yeang C, Ang L, Strachan M, DeMaria AN, Tsimikas S, Cotter B. The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting Angiology. 2017 Oct;68(9):795-798. doi: 10.1177/0003319716688415. Epub 2017 Jan 10. (PMID: 28068801) [Full Text]

Torzewski M, Ravandi A, Yeang C, Edel A, Bhindi R, Kath S, Twardowski L, Schmid J, Yang X, Franke UFW, Witztum JL, Tsimikas S. Lipoprotein(a) Associated Molecules are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis JACC Basic Transl Sci. 2017 Jun;2(3):229-240. doi: 10.1016/j.jacbts.2017.02.004. Epub 2017 Jun 26. (PMID: 29147686) (PMCID: PMC5685511) [Full Text]

Yeang C, Gordts PL, Tsimikas S. Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling: Adding the Plasminogen Receptor PlgR(KT) to the List Circ Res. 2017 Mar 31;120(7):1050-1052. doi: 10.1161/CIRCRESAHA.117.310700. (PMID: 28360338) (PMCID: PMC5470738) [Full Text]

Yeang C, Clopton PC, Tsimikas S. Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk J Clin Lipidol. 2016 Nov-Dec;10(6):1389-1396. doi: 10.1016/j.jacl.2016.09.012. Epub 2016 Sep 28. (PMID: 27919356) (PMCID: PMC8545497) [Full Text]

van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LA, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ES. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans Circulation. 2016 Aug 23;134(8):611-24. doi: 10.1161/CIRCULATIONAHA.116.020838. Epub 2016 Aug 5. (PMID: 27496857) (PMCID: PMC4995139) [Full Text]

Yeang C, Wilkinson MJ, Tsimikas S. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis Curr Opin Cardiol. 2016 Jul;31(4):440-50. doi: 10.1097/HCO.0000000000000300. (PMID: 27205885) (PMCID: PMC4956483) [Full Text]

Yeang C, Tsimikas S. The role of lipoprotein(a) in progression of renal disease: Causality or reverse causality? J Diabetes Complications. 2016 Jul;30(5):755-7. doi: 10.1016/j.jdiacomp.2016.04.001. Epub 2016 Apr 7. (PMID: 27118508) [Full Text]

Tavori H, Christian D, Minnier J, Plubell D, Shapiro MD, Yeang C, Giunzioni I, Croyal M, Duell PB, Lambert G, Tsimikas S, Fazio S. PCSK9 Association With Lipoprotein(a) Circ Res. 2016 Jun 24;119(1):29-35. doi: 10.1161/CIRCRESAHA.116.308811. Epub 2016 Apr 27. (PMID: 27121620) (PMCID: PMC4920709) [Full Text]

Yeang C, Hung MY, Byun YS, Clopton P, Yang X, Witztum JL, Tsimikas S. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a) J Clin Lipidol. 2016 May-Jun;10(3):594-603. doi: 10.1016/j.jacl.2016.01.005. Epub 2016 Mar 8. (PMID: 27206947) [Full Text]

Yeang C, Cotter B, Tsimikas S. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis Cardiovasc Drugs Ther. 2016 Feb;30(1):75-85. doi: 10.1007/s10557-015-6634-1. (PMID: 26780907) [Full Text]

Capoulade R, Chan KL, Yeang C, Mathieu P, Bossé Y, Dumesnil JG, Tam JW, Teo KK, Mahmut A, Yang X, Witztum JL, Arsenault BJ, Després JP, Pibarot P, Tsimikas S. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis J Am Coll Cardiol. 2015 Sep 15;66(11):1236-1246. doi: 10.1016/j.jacc.2015.07.020. (PMID: 26361154) [Full Text]

Yeang C, Tsimikas S. HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a) J Lipid Res. 2015 Jul;56(7):1241-4. doi: 10.1194/jlr.E060947. Epub 2015 May 26. (PMID: 26014961) (PMCID: PMC4479328) [Full Text]

Yeang C, Witztum JL, Tsimikas S. 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering Curr Opin Lipidol. 2015 Jun;26(3):169-78. doi: 10.1097/MOL.0000000000000171. (PMID: 25943842) [Full Text]

Briley-Saebo K, Yeang C, Witztum JL, Tsimikas S. Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions J Cardiovasc Transl Res. 2014 Nov;7(8):719-36. doi: 10.1007/s12265-014-9590-4. Epub 2014 Oct 9. (PMID: 25297940) (PMCID: PMC4233166) [Full Text]

Wilkinson MJ, Laffin LJ, Davidson MH. Overcoming toxicity and side-effects of lipid-lowering therapies Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):439-52. doi: 10.1016/j.beem.2014.01.006. Epub 2014 Jan 23. (PMID: 24840269) [Full Text]